Abstract
Obesity is a major threat to health worldwide and if the current trend continues, more than 50% of the world’s population is projected to be obese by the year 2030 [1]. As reviewed by Irwin et al. in another chapter [2], obesity has been linked to both cancer risk and cancer outcome. Although obesity, insulin resistance and hyperinsulinemia are interrelated [3], until recently the primary focus of epidemiologic and clinical cancer research has been on obesity. Eugenia Calle et al. [4] provided an elegant demonstration of the association between body size and mortality from cancer in the prospective Cancer Prevention Study II, conducted by the American Cancer Society. Studying over 900,000 American adults, they found that individuals with a body mass index (BMI = weight(kg)/height(m)2) of at least 40 had death rates from cancer that were 52% higher (for men) and 62% higher (for women) than the rates seen in normal weight individuals. Higher BMI was significantly associated with increased death rates from a number of common cancers, including colon and rectum, breast, uterus and prostate as well as from less common cancers such as liver, gallbladder, pancreas, kidney, stomach, cervix, non-Hodgkin’s lymphoma and multiple myeloma. The only cancer demonstrating an inverse association between BMI and future cancer mortality was lung cancer. The results of this study (which combine the effect of obesity on cancer risk and cancer progression) suggest that obesity may contribute to 14% of all deaths from cancer in men and 20% of all deaths from cancer in women, evidence of an important contribution of obesity to cancer death. Similar results were obtained in a recent study by Whitlock et al. [5] in an analysis involving approximately 90,000 subjects that obesity was associated with significantly increased mortality from several causes, including cancer; with every 5 kg/m2 increase in BMI, risk of cancer-specific mortality increased by 10%. Furthermore, a recent meta-analysis by Renehan et al. [6] that focused on cancer incidence rather than mortality, reported that increased BMI was associated with increased risk of several different cancers including esophageal, thyroid, colon, rectal, renal, endometrial, gallbladder, breast (postmenopausal) and pancreatic, as well as melanoma, leukaemia, multiple myeloma, and non-Hodgkin lymphoma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kelly T et al (2008) Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32(9):1431–1437
Pierce JP et al (2007) Re: dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 99(11):900; author reply 900–901
Clegg D (2009) Mechanisms of insulin resistance, obesity and metabolic syndrome. In: Fantus IG (ed) Insulin resistance and cancer. Springer, New York
Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638
Whitlock G et al (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373(9669):1083–1096
Renehan AG et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578
Friedenreich CM, Orenstein MR (2002) Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 132(11 Suppl):3456S–3464S
Friedenreich CM, Cust AE (2008) Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 42:636–647
Hursting SD et al (2008) Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab 22(4):659–669
Moore SC et al (2009) Age-specific physical activity and prostate cancer risk among white men and black men. Cancer 115(21):5060–5070
Renehan AG, Roberts DL, Dive C (2008) Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 114(1):71–83
Lipscombe L (2009) Insulin, insulin resistance and cancer associations. In: Fantus IG (ed) insulin resistance and cancer. Springer, New York
LeRoith D (2009) Animal models of hyperinsulinemia, insulin resistance and cancer. In: Fantus IG (ed) insulin resistance and cancer. Springer, New York
Fantus IG (2009) Potential mechanisms linking insulin to cancer. In: Fantus IG (ed) Insulin resistance and cancer. Springer, New York
Sonnenberg N (2009) Actions of insulin as a survival and growth factor: Akt/PKB, mTOR and regulation of translation. In: Fantus IG (ed) Insulin resistance and cancer. Springer, New York
Cantley LC (2009) Cancer cell metabolism and AMPK: regulation of cell proliferation and apoptosis. In: Fantus IG (ed) Insulin resistance and cancer. Springer, New York
Brodt P (2009) Insulin-like growth factors and cancer. In: Fantus IG (ed) Insulin resistance and cancer. Springer, New York
Belfiore A (2009) Insulin, IGF receptors and cancer. In: Fantus IG (ed) Insulin resistance and cancer. Springer, New York
Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114:63–70
Zhou XH et al (2010) Diabetes, prediabetes and cancer mortality. Diabetologia 53(9):1867–1876
Gunter MJ et al (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101(1):48–60
Vinikoor LC, Long MD, Keku TO et al (2009) The Association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. Cancer Epidemiol Biomark Prev 18:1239–1242
von Kriegstein E, von Kriegstein K (2007) Inhaled insulin for diabetes mellitus. N Engl J Med 356(20):2106; author reply 2108
Hemkens LG et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9):1732–1744
Jonasson JM et al (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52(9):1745–1754
Mannucci E et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997–2003
Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9):1755–1765
Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777
Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52(12):2499–2506
Lipscombe LL et al (2006) Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 98(3):349–356
Lipscombe LL et al (2006) Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98(3):303–309
Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86(3):s823–s835
Pierce BL et al (2008) Diabetes mellitus and prostate cancer risk. Prostate 68(10):1126–1132
Jee SH et al (2008) Body mass index and cancer risk in Korean men and women. Int J Cancer 123(8):1892–1896
Trevisan M et al (2001) Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomark Prev 10(9):937–941
Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635
Goodwin P (2006) Energy balance and prognosis: breast cancer. In: McTiernan A (ed) Cancer prevention and management through exercise and weight control. Taylor and Francis Group, Boca Raton
Goodwin PJ et al (2009) High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 114(3):517–525
Goodwin PJ et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51
Pasanisi P et al (2008) Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomark Prev 17(7):1719–1722
Pollak M et al (2006) Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J Clin Oncol ASCO Ann Meet Proc I 24(Suppl 18S):Abstract 524
Irwin ML et al (2011) Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 29(1):47–53
Duggan C et al (2011) Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29(1):32–39
Emaus A et al (2010) Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 121(3):651–660
Erickson K et al (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 29(1):54–60
Law JH et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238–10246
Holmes MD et al (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293(20):2479–2486
Abrahamson PE et al (2006) Recreational physical activity and survival among young women with breast cancer. Cancer 107(8):1777–1785
Holick CN et al (2008) Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomark Prev 17(2):379–386
Irwin ML et al (2003) Physical activity levels before and after a diagnosis of breast carcinoma: the health, eating, activity, and lifestyle (HEAL) study. Cancer 97(7):1746–1757
Sternfeld B et al (2009) Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. Cancer Epidemiol Biomark Prev 18(1):87–95
Enger SM, Bernstein L (2004) Exercise activity, body size and premenopausal breast cancer survival. Br J Cancer 90(11):2138–2141
Borugian MJ et al (2004) Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomark Prev 13(7):1163–1172
Mulligan AM et al (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106(1):39–47
Mathieu MC et al (1997) Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109(6):565–571
Frasca F et al (2008) The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114(1):23–37
Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):s843–s857
Skolarus TA, Wolin KY, Grubb RL 3rd (2007) The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 4(11):605–614
Magheli A et al (2008) Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 72(6):1246–1251
Motamedinia P et al (2008) Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology 72(5):1106–1110
Freedland SJ et al (2008) Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int 102(8):969–974
King CR, Spiotto MT, Kapp DS (2009) Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 73(4):1017–1022
Stroup SP et al (2007) Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer 110(5):1003–1009
Spangler E et al (2007) Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol 178(5):1939–1944; discussion 1945
Paaskesen CE, Borre M (2008) Body mass index and prognostic markers at radical prostatectomy. Scand J Urol Nephrol 42:230–236
Merrick GS et al (2007) Obesity is not predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol 30(6):588–596
Halabi S et al (2007) Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 110(7):1478–1484
Lehrer S et al (2002) Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 87(7):726–728
Hammarsten J, Hogstedt B (2005) Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 41(18):2887–2895
Ma J et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047
Cox ME et al (2009) Insulin receptor expression by human prostate cancers. Prostate 69(1):33–40
Dignam JJ et al (2006) Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98(22):1647–1654
Meyerhardt JA et al (2003) Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98(3):484–495
Meyerhardt JA et al (2008) Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26(25):4109–4115
Moon HG et al (2008) Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol 15(7):1918–1922
Wolpin BM et al (2009) Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27(2):176–185
Siddiqui AA et al (2008) Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 53(9):2486–2494
Nickelsen TN, Jorgensen T, Kronborg O (2005) Lifestyle and 30-day complications to surgery for colorectal cancer. Acta Oncol 44(3):218–223
Haydon AM et al (2006) Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55(1):62–67
Dray X et al (2003) Influence of dietary factors on colorectal cancer survival. Gut 52(6):868–873
Meyerhardt JA et al (2006) Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24(22):3527–3534
Meyerhardt JA et al (2009) Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res 15(18):5931–5936
Meyerhardt JA et al (2009) Physical activity and male colorectal cancer survival. Arch Intern Med 169(22):2102–2108
Hickish T et al (2009) Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst 101(7):537
Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G (2008) Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag 4(4):825–836
Barone BB et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764
Peairs KS et al (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–6
Chlebowski RT et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776
ACS report: half of cancer deaths could be prevented. CA Cancer J Clin 2005; 55(4):209–210
Miller JP et al (1994) Strength training increases insulin action in healthy 50- to 65-yr-old men. J Appl Physiol 77(3):1122–1127
Kirwan JP et al (1993) Endurance exercise training reduces glucose-stimulated insulin levels in 60- to 70-year-old men and women. J Gerontol 48(3):M84–M90
Craig BW, Everhart J, Brown R (1989) The influence of high-resistance training on glucose tolerance in young and elderly subjects. Mech Ageing Dev 49(2):147–157
Gill T, King L, Caterson I (2005) Obesity prevention: necessary and possible. A structured approach for effective planning. Proc Nutr Soc 64(2):255–261
Glenny AM et al (1997) The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 21(9):715–737
Franz MJ et al (2007) Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 107(10):1755–1767
Ogden CL et al (2007) The epidemiology of obesity. Gastroenterology 132(6):2087–2102
Gill T (2002) Importance of preventing weight gain in adulthood. Asia Pac J Clin Nutr 11(Suppl 3):S632–S636
Lemmens VE et al (2008) A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults. Obes Rev 9(5):446–455
Van Dorsten B, Lindley EM (2008) Cognitive and behavioral approaches in the treatment of obesity. Endocrinol Metab Clin North Am 37(4):905–922
Shaw M et al (2009) Effect of a successful intensive lifestyle program on insulin sensitivity and glucose tolerance in obese youth. Diabetes Care 32(1):45–47
Cummings S, Apovian CM, Khaodhiar L (2008) Obesity surgery: evidence for diabetes prevention/management. J Am Diet Assoc 108(4 Suppl 1):S40–S44
Sjostrom L et al (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8):741–752
Knowler WC et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403
Orchard TJ et al (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142(8):611–619
Tuomilehto J et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343–1350
Ilanne-Parikka P et al (2008) Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 31(4):805–807
Oh EG et al (2011) Effects of a therapeutic lifestyle modification program on inflammatory chemokines and insulin resistance in subjects with metabolic syndrome. Biol Res Nurs 13(2):182–188
Hemmingsson E, Udden J, Rossner S (2011) Diet and physical activity interventions in severely obese adults. JAMA 305(6):563–564; author reply 564
Howell A, Chapman M, Harvie M (2009) Energy restriction for breast cancer prevention. Recent Results Cancer Res 181:97–111
Rooney M, Wald A (2007) Interventions for the management of weight and body composition changes in women with breast cancer. Clin J Oncol Nurs 11(1):41–52
Markes M, Brockow T, Resch KL (2006) Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev (4):CD005001
Schmitz KH et al (2005) Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 14(7):1588–1595
McNeely ML et al (2006) Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ 175(1):34–41
Knols R et al (2005) Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol 23(16):3830–3842
Courneya KS, Friedenreich CM (2007) Physical activity and cancer control. Semin Oncol Nurs 23(4):242–252
Blackburn GL, Wang KA (2007) Dietary fat reduction and breast cancer outcome: results from the Women’s Intervention Nutrition Study (WINS). Am J Clin Nutr 86(3):s878–s881
Pierce JP et al (2007) Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA 298(3):289–298
Rock CL et al (2009) Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women’s Healthy Eating and Living Study. Cancer Epidemiol Biomark Prev 18(2):486–494
Schmitz KH, Ahmed RL, Hannan PJ et al (2005) Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomark Prev 14:1672–1680
Ligibel JA et al (2008) Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26(6):907–912
Irwin ML et al (2009) Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomark Prev 18(1):306–313
Schmitz KH et al (2005) Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomark Prev 14(7):1672–1680
Fairey AS et al (2003) Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomark Prev 12(8):721–727
Goodwin PJ (2008) Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 26(6):833–834
Padwal R, Li SK, Lau DC (2004) Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev (3):CD004094
Sachdev D (2010) Targeting the type 1 insulin-like growth factor system for breast cancer therapy. Curr Drug Targets 11:1121–1132
Padwal R, Li SK, Lau DC (2004). Cochrane Database Syst Rev CD004094
Cusi K, DeFronzo RA (1998) Metformin: a review of its metabolic effects. Diab Rev 6:89–131
Zhou G et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167–1174
Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100(3):328–341
Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5):577–590
Anisimov VN et al (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40(8–9):685–693
Huang X et al (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412(2):211–221
Buzzai M et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67(14):6745–6752
Zhuang Y, Miskimins WK (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18
Wang LW et al (2008) Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14(47):7192–7198
Beckner ME et al (2005) Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest 85(12):1457–1470
Isakovic A et al (2007) Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64(10):1290–1302
Decensi A et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3(11):1451–1461
Jiralerspong S et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297–3302
Mazzone PJ et al (2010) The effect of metformin and thiazolidinedione use on lung cancer. Chest 138:882A
Hosono K et al (2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3(9):1077–1083
Niraula S et al (2010) Clinical and biologic effects of metformin in early stage breast cancer [PD03-06]. San Antonio Breast Cancer Symphosium. pp 8–10
Bonanni B et al (2010) A randomized pre-surgical trial of metformin in breast cancer. Preliminary feasibility and safety results. San Antonio Breast Cancer Symphosium [PD03-02]
Hadad S et al (2009) The effect of neoadjuvant metformin on breast cancer related genes clinical trial – a preliminary result. San Antonio Breast Cancer Symphosium (Abstract# 3145)
Goodwin PJ, Ligibel JA, Stambolic V (2009) Metformin in breast cancer: time for action. J Clin Oncol 27(20):3271–3273
Cazzaniga M et al (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomark Prev 18(3):701–705
Blanquicett C, Roman J, Hart CM (2008) Thiazolidinediones as anti-cancer agents. Cancer Ther 6(A):25–34
Govindarajan R et al (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25(12):1476–1481
Hassan MM et al (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938–1946
Tolman KG (2011) The safety of thiazolidinediones. Expert Opin Drug Saf
Holmes MD, Chen WY, Feskanich D et al (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486
Pierce JP et al (2007) Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25(17):2345–2351
Irwin ML et al (2008) Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol 26(24):3958–3964
Friedenreich CM et al (2009) Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer 124(8):1954–1962
West-Wright CN et al (2009) Long-term and recent recreational physical activity and survival after breast cancer: the California Teachers Study. Cancer Epidemiol Biomark Prev 18(11):2851–2859
Keegan TH et al (2010) Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry. Breast Cancer Res Treat 123(2):531–542
Bertram LA et al (2011) Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study. Cancer Causes Control 22(3):427–435
Fairey AS, Courneya KS, Field CJ et al (2003) Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomark Prev 12:721–727
Ligibel JA, Campbell N, Partridge A et al (2008) Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26:907–912
Irwin ML, Varma K, Alvarez-Reeves M et al (2009) Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomark Prev 18:306–313
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Niraula, S., Goodwin, P.J. (2011). Insulin Resistance: Clinical Implications for Cancer Treatment and Prevention. In: Fantus, I. (eds) Insulin Resistance and Cancer. Energy Balance and Cancer, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9911-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9911-5_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-9910-8
Online ISBN: 978-1-4419-9911-5
eBook Packages: MedicineMedicine (R0)